NeoGenomics, Inc. Stock News
$7.87
0.06%
yesterday
Nasdaq,
Sep 25, 10:00 pm CET
Index
Industry
NeoGenomics, Inc. Stock News
Neutral
Business Wire
●
28 days ago
FORT MYERS, Fla.--(BUSINESS WIRE)--Court Rules for NeoGenomics in Patent Infringement Lawsuit Against Natera.
Neutral
Seeking Alpha
●
about one month ago
Neo Performance Materials Inc. (OTCPK:NOPMF) Q2 2025 Earnings Conference August 12, 2025 10:00 AM ET Company Participants Irina Kuznetsova - Corporate Participant Jonathan Baksh - Executive VP & CFO Rahim Suleman - CEO, President & Director Conference Call Participants Ian Brooks Gillies - Stifel Nicolaus Canada Inc., Research Division J. Marvin Wolff - Paradigm Capital Inc., Research Division ...
Neutral
Business Wire
●
about 2 months ago
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics launched the NEO PanTracer™ LBx, a blood-based comprehensive genomic profiling test, expanding the company's PanTracer portfolio.
Neutral
Seeking Alpha
●
about 2 months ago
NeoGenomics, Inc. (NASDAQ:NEO ) Q2 2025 Earnings Conference Call July 29, 2025 8:30 AM ET Company Participants Anthony P. Zook - CEO & Director Jeffrey S.
Neutral
Business Wire
●
about 2 months ago
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics announced its second-quarter results for the period ended June 30, 2025.
Neutral
Business Wire
●
3 months ago
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will report its second quarter 2025 financial results prior to the open of the U.S. financial markets on Tuesday, July 29, 2025.
Neutral
Business Wire
●
3 months ago
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics launched PanTracer™ Tissue, a next-generation solid tumor profiling assay, with the option to add HRD testing.
Neutral
Business Wire
●
3 months ago
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics announced the appointment of Marjorie Green to its Board of Directors, effective June 19, 2025.
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
